Fat Loss
Tesamorelin
The Visceral Fat Protocol
The only FDA-approved peptide for visceral fat reduction. Pulsatile growth hormone release, targeted deep-organ fat loss, and a 26-week clinical evidence base. Reconstitution, daily dosing, blood monitoring, and realistic timelines.
FDA Status
Approved 2010 as Egrifta®
Primary Effect
Targeted visceral fat reduction
Clinical Result
15.2% mean visceral fat reduction (Phase III)
Dose
2 mg daily · Before bed
Who this guide is for.
Those with stubborn visceral (belly) fat who need a clinically proven, FDA-approved approach with measurable results at 6–8 weeks.
What's Inside
32 pages. 12 chapters.
Not a blog post. A protocol.
Evidence-Based
Every dosing recommendation is grounded in clinical research and practitioner protocols — not forum anecdotes.
Action-Ready
Not theory — a step-by-step operating manual from first reconstitution to cycle end.
Safety-First
Full side effect profiles, contraindications, and monitoring requirements. No information withheld.
Get the Tesamorelin guide.
32 pages. 12 chapters. Everything from reconstitution to cycle end — in one PDF.